ADVERSE REACTIONS OF DACARBAZINE IN PEDIATRIC ONCOLOGY; A CASE SERIES FROM A TERTIARY CARE CANCER SPECIALTY HOSPITAL, PAKISTAN
Saleha Nadeem, Ehsan Elahi, Shahbaz Ahmad Khan, Sidrah Andleeb
Department of pharmaceutical services, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan
Keywords: Pediatric Hodgkin’s Lymphoma, Adverse Drug Reactions, Dacarbazine, Case Series
Hodgkin’s lymphoma in pediatric patients involves chemotherapy drug regimens containing Dacarbazine as a backbone of the therapy. Adverse drug events are the major concerns in the treatment plan of chemotherapy. Here in this case series, we present five cases of Hodgkin’s lymphoma of pediatric age group getting treated with Dacarbazine based chemotherapy either COPDac or ABVD. All patients developed shivering during the infusion. Three of them had fever spikes and one patient happened to have tachycardia. All the events were managed conservatively followed by safe administration of chemotherapy. Four patients are continuing to have treatment as per the plan and one patient is with end of treatment and on follow up. Naranjo’s scale was used for probability assessment of the events and score of 6 was given to all the events, indicating the adverse drug reactions to be probable. A very scarce data and our case series are evocative of further studies to review the administration time of the Dacarbazine as well as the addition of pre-medication before initiation of Dacarbazine infusion.
© 2016 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made.
You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits